|
|
 |
|
Viewing report
|
|
|
|
Competitor Analysis: HPV Vaccines
La Merie Publishing, May 2010, Pages: 18
The present Competitive Intelligence Report about HPV Vaccines provides a competitor evaluation in the field of investigational vaccines against infection with the human papilloma virus (HPV) for prophylaxis of genital and anal warts and of cervical precancer as of May 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Genital human papilloma virus is one of the most common sexually transmitted infections (STI). Two vaccines are commercially available to protect females against the types of HPV that cause most cervical cancers. One of these vaccines also protects against most genital warts. Both vaccines are recommended for 11 and 12 year-old girls, and for females 13 through 26 years old, who did not get any or all of the three recommended doses when they were younger. The approved vaccines protect against two or four, respectively, most common types of HPV. A number of further vaccine candidates are in development utilizing various technologies for expression of the antigens and various adjuvants. Some vaccines also are directed against more or different types of HPV or are designed as therapeutic vaccines by induction of T cell immunity.
The report includes a compilation of currently active projects in development of vaccines targeting various types of human papilloma virus for prophylaxis of genitoanal warts and cervical precancer (cervical intraepithelial neoplasia or CIN). In addition, the report lists company-specific R&D pipelines of HPC Vaccines. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Index;
- HPV Vaccines
- Corporate HPV Vaccines R&D Pipelines
- About La Merie
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Competitor Analysis: Herpes Virus Vaccines and Therapeutics
Vaccine Pipeline Database: 1-Year Subscription
Human Papillomavirus Infections - Pipeline Review, H2 2011
Competitor Analysis - Dengue Virus Vaccines
Competitor Analysis - Hepatitis Vaccines
Human Papillomavirus (HPV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Human Vaccines - Global Strategic Business Report
Competitor Analysis: Cytomegalovirus (CMV) Vaccines and Therapeutics
Competitor Analysis: Anti-Infective Antibodies
Competitor Analysis: RSV Vaccines and Therapeutics
|
|
|
|
